Current treatment in Alzheimer’s disease (AD) is initiated at a stage where the brain already has irreversible structural deteriorations. Therefore, the concept of treatment prior to obvious cognitive deficits has become widely accepted, and simple biochemical tests to discriminate normal aging from prodromal or demented stages are now common practice.
Objective:
The objective of the study was the differentiation of controls, mild cognitive impairment (MCI) and AD patients by novel blood-based assays in combination with neuropsychological tests.
Methods:
In a cross-sectional study, 143 subjects aged 18 to 85 years were recruited. All participants were classified by a comprehensive neuropsychological assessment. Blood samples were analyzed for several amyloid-β (Aβ) species, pro-inflammatory markers, anti-Aβ autoantibodies, and ApoE allele status, respectively.
Results:
Plasma Aβ1-42 was significantly decreased in MCI and AD compared to age-matched controls, whereas Aβ1-40 did not differ, but increases with age in healthy controls. The Aβ1-42 to Aβ1-40 ratio was stepwise decreased from age-matched controls via MCI to AD, and shows a clear correlation with memory scores. Reduced Aβ1-42 and Aβ1-42 to Aβ1-40 ratio have strongly correlated with carrying ApoE ɛ4 allele. Autoantibodies against pyroglutamate-modified Aβ, but only a certain subclass, were significantly decreased in AD compared to MCI and age-matched controls, whereas autoantibodies against the unmodified N-terminus of Aβ did not differ.
Conclusion:
Comprehensive sample preparation and assay standardization enable reliable usage of plasma Aβ for diagnosis of MCI and AD. Anti-pGlu-Aβ autoantibodies correlate with cognition, but not with ApoE, supporting the associated plasma Aβ analysis with additional and independent information.
CitronM (2004) Strategies for disease modification in Alzheimer’s disease. Nat Rev Neurosci5, 677–685.
2.
GlennerGG, WongCW (1984) Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun120, 885–890.
3.
Grundke-IqbalI, IqbalK, TungYC, QuinlanM, WisniewskiHM, BinderLI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A83, 4913–4917.
4.
EikelenboomP, RozemullerAJ, HoozemansJJ, VeerhuisR, van GoolWA (2000) Neuroinflammation and Alzheimer disease: Clinical and therapeutic implications. Alzheimer Dis Assoc Disord14(Suppl 1), S54–S61.
5.
EschweilerGW, LeyheT, KlöppelS, HüllM (2010) New developments in the diagnosis of dementia. Dtsch Arztebl Int107, 677–683.
6.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, MayeuxR, MyersRH, Pericak-VanceMA, RischN, van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA278, 1349–1356.
7.
GalimbertiD, SchoonenboomN, ScarpiniE, ScheltensP, Dutch-Italian Alzheimer Research Group (2003) Chemokines in serum and cerebrospinal fluid of Alzheimer’s disease patients. Ann Neurol53, 547–548.
KoyamaA, OkerekeOI, YangT, BlackerD, SelkoeDJ, GrodsteinF (2012) Plasma amyloid-ß as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. Arch Neurol69, 824–831.
12.
ReisbergB (2001) Dementia: Overview. In International Encyclopedia of the Social & Behavioral Sciences, SmelserNJ, BaltesPB eds. Pergamon, Oxford, pp. 3389–3396.
13.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
14.
PetersenRC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med256, 183–194.
15.
FrodlT, CarballedoA, HughesMM, SalehK, FaganA, SkokauskasN, ConnorTJ (2012) Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: High IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder.e. Transl Psychiatry2, 88.
16.
Elderkin-ThompsonV, IrwinMR, HellemannG, KumarA (2012) Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults. Am J Geriatr Psychiatry20, 753–763.
17.
ArnoldS, XieS, LeungYY (2012) Plasma biomarkers of depressive symptoms in older adults.e. Transl Psychiatry2, 65.
18.
CynisH, HoffmannT, FriedrichD, KehlenA, GansK, KleinschmidtM, RahfeldJU, WolfR, WermannM, StephanA, HaegeleM, SedlmeierR, GraubnerS, JaglaW, MüllerA, EichentopfR, HeiserU, SeifertF, QuaxPH, de VriesMR, HesseI, TrautweinD, WollertU, BergS, FreyseEJ, SchillingS, DemuthHU (2011) The isoenzyme of glutaminylcyclase is an important regulator of monocyte infiltration under inflammatory conditions. EMBO Mol Med3, 545–558.
19.
MaillyF, DavignonJ, NestruckAC (1990) Analytical isoelectric focusing with immobilized pH gradients of human apolipoprotein E from very low density lipoproteins and total plasma. J Lipid Res31, 149–155.
20.
LuleyC, BaumstarkMW, WielandH (1991) Rapid apolipoprotein E phenotyping by immunofixation in agarose. J Lipid Res32, 880–883.
21.
SatzgerW, HampelH, PadbergF, BürgerK, NoldeT, IngrassiaG, EngelR (2001) Zur praktischen Anwendung der CERAD-Testbatterie als neuropsychologisches Demenzscreening. Der Nervenarzt72, 196–203.
ReitanRM (1944) Army Individual Test Battery. Manual of Directions and Scoring. War Department, Adjutant General’s Office, Washington, DC.
27.
TombaughTN, ReesL, McIntyreN (1998) Normative data for the Trail Making Test. Personal communication cited in A compendium of neuropsychological tests: Administration, norms and commentary (2nd ed.), SpreenO, StraussE, eds, Oxford University Press, New York.
28.
WechslerD (1981) Wechsler Adult Intelligence Scale - Revised, The Psychological Corporation, New York.
29.
TewesU (1991) HAWIE-R: Hamburg-Wechsler Intelligenztest für Erwachsene. Handbuch und Testanweisung. Verlag Hans Huber, Bern, Switzerland.
LeplowB, FriegeL (1998) Eine Sozialformel zur Schaetzung der praemorbiden Intelligenz. Zeitsch f Klin Psych21, 1–8.
32.
SchinkaJS, VanderploegRD (2000) Estimating premorbid level of functioning. In Clinicians guide to neuropsychological assessment (2nd ed.), VanderploegRD, ed. Erlbaum Associates, Inc., Mahwah, NJ, pp. 37–63.
33.
IhlR, FrölichL (1991) Die Reisberg-Skalen GDS, BCRS, FAST - Manual. Beltz, Weinheim, Germany.
34.
HerrmannCh, BussU, Snaith, RP (1995) HADS-D - Hospital Anxiety and Depression Scale - Deutsche Version: Ein Fragebogen zur Erfassung von Angst und Depressivität in der somatischen Medizin. Verlag Hans Huber, Bern, Switzerland.
35.
BeckAT, WardCH, MendelsonM, MockJ, ErbaughJ (1961) An inventory for measuring depression. Arch Gen Psychiatry4, 561–571.
36.
BritschgiM, OlinCE, JohnsHT, Takeda-UchimuraY, LeMieuxMC, RufibachK, RajadasJ, ZhangH, TomookaB, RobinsonWH, ClarkCM, FaganAM, GalaskoDR, HoltzmanDM, JutelM, KayeJA, LemereCA, LeszekJ, LiG, PeskindER, QuinnJF, YesavageJA, GhisoJA, Wyss-CorayT (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc Natl Acad Sci U S A106, 12145–12150.
37.
MarcelloA, WirthsO, Schneider-AxmannT, Degerman-GunnarssonM, LannfeltL, BayerTA (2011) Reduced levels of IgM autoantibodies against N-truncated pyroglutamateAß in plasma of patients with Alzheimer’s disease. Neurobiol Aging32, 1379–1387.
38.
HuangCW, WangSJ, WuSJ, YangCC, HuangMW, LinCH, ChengIH (2013) Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer’s disease. Am J Alzheimers Dis Other Demen28, 75–83.
39.
KoyamaA, O’BrienJ, WeuveJ, BlackerD, MettiAL, YaffeK (2013) The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: A meta-analysis. J Gerontol A Biol Sci Med Sci68, 433–440.
40.
LewczukP, PoppJ, LelentalN, KölschH, MaierW, KornhuberJ, JessenF (2012) Cerebrospinal fluid soluble amyloid-ß protein precursor as a potential novel biomarkers of Alzheimer’s disease. J Alzheimers Dis28, 119–125.
41.
HanssonO, StomrudE, VanmechelenE, ÖstlingS, GustafsonDR, ZetterbergH, BlennowK, SkoogI (2012) Evaluation of plasma A(as predictor of Alzheimer’s disease in older individuals without dementia: A population-based study. J Alzheimers Dis28, 231–238.
42.
CorboRM, ScacchiR, MuredduL, MulasG, AlfanoG (1995) Apolipoprotein E polymorphism in Italy investigated in native plasma by a simple polyacrylamide gel isoelectric focusing technique. Comparison with frequency data of other European populations. Ann Hum Genet59, 197–209.
LambertJC, Schraen-MaschkeS, RichardF, FievetN, RouaudO, BerrC, DartiguesJF, TzourioC, AlpérovitchA, BuéeL, AmouyelP (2009) Association of plasma amyloid beta with risk of dementia: The prospective Three-City Study. Neurology73, 847–853.
45.
CreanS, WardA, MercaldiCJ, CollinsJM, CookMN, BakerNL, ArrighiHM (2011) Apolipoprotein E e4 prevalence in Alzheimer’s disease patients varies across global populations: A systematic literature review and meta-analysis. Dement Geriatr Cogn Disord31, 20–30.
46.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
47.
RoherAE, LowensonJD, ClarkeS, WoodsAS, CotterRJ, GowingE, BallMJ (1993) beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A90, 10836–10840.
48.
AndreasenN, HesseC, DavidssonP, MinthonL, WallinA, WinbladB, VandersticheleH, VanmechelenE, BlennowK (1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol56, 673–680.
49.
VandersticheleH, Van KerschaverE, HesseC, DavidssonP, BuyseMA, AndreasenN, MinthonL, WallinA, BlennowK, VanmechelenE (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid7, 245–258.
50.
SunderlandT, LinkerG, MirzaN, PutnamKT, FriedmanDL, KimmelLH, BergesonJ, ManettiGJ, ZimmermannM, TangB, BartkoJJ, CohenRM (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer’s disease. JAMA289, 2094–2103.
51.
HanssonO, ZetterbergH, VanmechelenE, VandersticheleH, AndreassonU, LondosE, WallinA, MinthonL, BlennowK (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging31, 357–367.
52.
TamaokaA, FukushimaT, SawamuraN, IshikawaK, OguniE, KomatsuzakiY, ShojiS (1996) Amyloid beta protein in plasma from patients with sporadic Alzheimer’s disease. J Neurol Sci141, 65–68.
53.
KosakaT, ImagawaM, SekiK, AraiH, SasakiH, TsujiS, Asami-OdakaA, FukushimaT, ImaiK, IwatsuboT (1997) The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology48, 741–745.
54.
MehtaPD, PirttiläT, MehtaSP, SersenEA, AisenPS, WisniewskiHM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol57, 100–105.
55.
FukumotoH, TennisM, LocascioJJ, HymanBT, GrowdonJH, IrizarryMC (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol60, 958–964.
56.
SobówT, FlirskiM, KloszewskaI, LiberskiPP (2005) Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer’s disease. Acta Neurobiol Exp (Wars)65, 117–124.
57.
BiereAL, OstaszewskiB, StimsonER, HymanBT, MaggioJE, SelkoeDJ (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem271, 32916–32922.
58.
HughesSR, KhorkovaO, GoyalS, KnaebleinJ, HerouxJ, RiedelNG, SahasrabudheS (1998) Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci U S A95, 3275–3280.
59.
KuoYM, KokjohnTA, KalbackW, LuehrsD, GalaskoDR, ChevallierN, KooEH, EmmerlingMR, RoherAE (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochem Biophys Res Commun268, 750–756.
SmithCC, BetteridgeDJ (2004) Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans. Neurosci Lett367, 48–50.
62.
PesaresiM, LovatiC, BertoraP, MaillandE, GalimbertiD, ScarpiniE, QuadriP, ForloniG, MarianiC (2006) Plasma levels of beta-amyloid (1-42) in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging27, 904–905.
63.
LuiJK, LawsSM, LiQX, VillemagneVL, AmesD, BrownB, BushAI, De RuyckK, DromeyJ, EllisKA, FauxNG, FosterJ, FowlerC, GuptaV, HudsonP, LaughtonK, MastersCL, PertileK, RembachA, RimajovaM, RodriguesM, RoweCC, RumbleR, SzoekeC, TaddeiK, TaddeiT, TrounsonB, WardV, MartinsRN, AIBL Research Group (2010) Plasma amyloid-beta as a biomarker in Alzheimer’s disease: The AIBL study of aging. J Alzheimers Dis20, 1233–1242.
64.
MayeuxR, HonigLS, TangMX, ManlyJ, SternY, SchupfN, MehtaPD (2003) Plasma Aß40 and Aß42 and Alzheimer’s disease: Relation to age, mortality, and risk. Neurology61, 1185–1190.
65.
SchupfN, TangMX, FukuyamaH, ManlyJ, AndrewsH, MehtaP, RavetchJ, MayeuxR (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci U S A105, 14052–14057.
66.
van OijenM, HofmanA, SoaresHD, KoudstaalPJ, BretelerMM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol5, 655–660.
67.
BlennowK, De MeyerG, HanssonO, MinthonL, WallinA, ZetterbergH, LewczukP, VandersticheleH, VanmechelenE, KornhuberJ, WiltfangJ, KND-Study Group, HeuserI, MaierW, LuckhausC, RütherE, HüllM, JahnH, GertzHJ, FrölichL, HampelH, PernetzkiR (2009) Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment. J Nutr Health Aging13, 205–208.
68.
Graff-RadfordNR, CrookJE, LucasJ, BoeveBF, KnopmanDS, IvnikRJ, SmithGE, YounkinLH, PetersenRC, YounkinSG (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol64, 354–362.
69.
LewczukP, KornhuberJ, VanmechelenE, PetersO, HeuserI, MaierW, JessenF, BürgerK, HampelH, FrölichL, HennF, FalkaiP, RütherE, JahnH, LuckhausCh, PerneczkyR, SchmidtkeK, SchröderJ, KesslerH, PantelJ, GertzHJ, VandersticheleH, de MeyerG, ShapiroF, WolfS, BiblM, WiltfangJ (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: A multicenter study with multiplexing. Exp Neurol223, 366–370.
70.
PrinceJA, ZetterbergH, AndreasenN, MarcussonJ, BlennowK (2004) APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology62, 2116–2118.
71.
VemuriP, WisteHJ, WeigandSD, KnopmanDS, ShawLM, TrojanowskiJQ, AisenPS, WeinerM, PetersenRC, JackCRJr (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol67, 308–316.
KuoYM, EmmerlingMR, WoodsAS, CotterRJ, RoherAE (1997) Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun237, 188–191.
75.
PicciniA, RussoC, GliozziA, ReliniA, VitaliA, BorghiR, GilibertoL, ArmirottiA, D’ArrigoC, BachiA, CattaneoA, CanaleC, TorrassaS, SaidoTC, MarkesberyW, GambettiP, TabatonM (2005) beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem280, 34186–34192.
76.
GüntertA, DöbeliH, BohrmannB (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience143, 461–475.
77.
WuG, MillerRA, ConnollyB, MarcusJ, RengerJ, SavageMJ (2014) Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer’s disease familial mutant knock-in mouse and Alzheimer’s disease brain. Neurodegener Dis14, 53–66.
DuY, DodelR, HampelH, BuergerK, LinS, EastwoodB, BalesK, GaoF, MoellerHJ, OertelW, FarlowM, PaulS (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer’s disease. Neurology57, 801–805.
80.
MoirRD, TseitlinKA, SosciaS, HymanBT, IrizarryMC, TanziRE (2005) Autoantibodies to redox-modified oligomericAbetaare attenuated in the plasma of Alzheimer’s disease patients. J Biol Chem280, 17458–17463.
81.
HymanBT, SmithC, BuldyrevI, WhelanC, BrownH, TangMX, MayeuxR (2001) Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann Neurol49, 808–810.
82.
MruthintiS, BuccafuscoJJ, HillWD, WallerJL, JacksonTW, ZamriniEY, SchadeRF (2004) Autoimmunity in Alzheimer’s disease: Increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging25, 1023–1032.
83.
StoraceD, CammarataS, BorghiR, SanguinetiR, GilibertoL, PicciniA, PolleroV, NovelloC, CaltagironeC, SmithMA, BossùP, PerryG, OdettiP, TabatonM (2010) Elevation of beta-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Arch Neurol67, 867–872.
84.
StrohmeyerR, Rogers (2001) Molecular and cellular mediators of Alzheimer’s disease inflammation. J Alzheimers Dis3, 131–157.
85.
SokolovaA, HillMD, RahimiF, WardenLA, HallidayGM, ShepherdCE (2009) Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer’s disease. Brain Pathol19, 392–398.
86.
KálmánJ, JuhászA, LairdG, DickensP, JárdánházyT, RimanóczyA, BonczI, Parry-JonesWL, JankaZ (1997) Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer’s disease. Acta Neurol Scand96, 236–240.
87.
AngelisP, ScharfS, ManderA, VajdaF, ChristophidisN (1998) Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer’s disease. Neurosci Lett244, 106–108.
88.
LanzreinAS, JohnstonCM, PerryVH, JobstKA, KingEM, SmithAD (1998) Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer’s disease: Interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord12, 215–227.
89.
FlirskiM, SobowT (2005) Biochemical markers and risk factors of Alzheimer’s disease. Curr Alzheimer Res2, 47–64.
